ZA202209826B - Inactivated sars-cov-2 virus vaccine - Google Patents

Inactivated sars-cov-2 virus vaccine

Info

Publication number
ZA202209826B
ZA202209826B ZA2022/09826A ZA202209826A ZA202209826B ZA 202209826 B ZA202209826 B ZA 202209826B ZA 2022/09826 A ZA2022/09826 A ZA 2022/09826A ZA 202209826 A ZA202209826 A ZA 202209826A ZA 202209826 B ZA202209826 B ZA 202209826B
Authority
ZA
South Africa
Prior art keywords
cov
virus vaccine
inactivated sars
sars
inactivated
Prior art date
Application number
ZA2022/09826A
Inventor
Andreas Meinke
Michael Möhlen
Robert Schlegl
Jürgen Heindl-Wruss
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Priority claimed from PCT/EP2021/058974 external-priority patent/WO2021204825A2/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of ZA202209826B publication Critical patent/ZA202209826B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ZA2022/09826A 2020-04-06 2022-09-02 Inactivated sars-cov-2 virus vaccine ZA202209826B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20202118 2020-10-15
EP20211853 2020-12-04
EP21154647 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160913 2021-03-05
PCT/EP2021/058974 WO2021204825A2 (en) 2020-04-06 2021-04-06 INACTIVATED SARS-CoV-2 VIRUS VACCINE

Publications (1)

Publication Number Publication Date
ZA202209826B true ZA202209826B (en) 2023-05-31

Family

ID=79566178

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/09826A ZA202209826B (en) 2020-04-06 2022-09-02 Inactivated sars-cov-2 virus vaccine

Country Status (13)

Country Link
EP (1) EP3955959A2 (en)
JP (1) JP2023520521A (en)
KR (1) KR20220164500A (en)
CN (1) CN115768469A (en)
AU (1) AU2021253605A1 (en)
BR (1) BR112022020100A2 (en)
CA (1) CA3168784A1 (en)
CL (1) CL2022002365A1 (en)
CO (1) CO2022013715A2 (en)
EC (1) ECSP22072590A (en)
IL (1) IL296072A (en)
MX (1) MX2022012447A (en)
ZA (1) ZA202209826B (en)

Also Published As

Publication number Publication date
CA3168784A1 (en) 2021-10-14
AU2021253605A1 (en) 2022-10-06
MX2022012447A (en) 2022-10-27
ECSP22072590A (en) 2022-10-31
CL2022002365A1 (en) 2023-02-03
CO2022013715A2 (en) 2022-12-30
BR112022020100A2 (en) 2022-11-29
CN115768469A (en) 2023-03-07
IL296072A (en) 2022-11-01
EP3955959A2 (en) 2022-02-23
JP2023520521A (en) 2023-05-17
KR20220164500A (en) 2022-12-13

Similar Documents

Publication Publication Date Title
GB2592769B (en) CpG-Adjuvanted SARS-CoV-2 virus vaccine
GB202002166D0 (en) Vaccine
IL275849A (en) Influenza virus vaccines and uses thereof
IL290924A (en) Hepatitis b virus vaccines
EP3866847A4 (en) Virus vaccine
ZA202209826B (en) Inactivated sars-cov-2 virus vaccine
GB202004825D0 (en) Influenza vaccines
GB202016954D0 (en) Vaccine
GB202314629D0 (en) Influenza virus vaccines
GB202306220D0 (en) Influenza virus vaccines
EP3600404A4 (en) Development of an alternative modified live influenza b virus vaccine
GB202114328D0 (en) Influenza vaccines
AU2022257033A1 (en) Pseudorabies virus vaccine
GB202315888D0 (en) Influenza vaccines
GB202213958D0 (en) Influenza vaccines
GB202208070D0 (en) Influenza vaccines
GB202009414D0 (en) Vaccine antigens
GB202119115D0 (en) Vaccine
GB202118110D0 (en) Vaccine
GB202020143D0 (en) HIV vaccine
GB202114274D0 (en) SARS-CoV-2 vaccine
GB202017646D0 (en) HIV Vaccine
GB202112149D0 (en) Shigellla vaccine
GB202102677D0 (en) Vaccine
GB202016165D0 (en) Vaccine